移植肾抗体介导的排斥反应的发病机制研究进展

廖涛; 孙启全

doi:10.3969/j.issn.1674-7445.2015.04.015

移植肾抗体介导的排斥反应的发病机制研究进展

doi: 10.3969/j.issn.1674-7445.2015.04.015

廖涛,
孙启全^,

510760 广州, 中山大学附属第三医院肾移植科中山大学器官移植研究所

基金项目:

国家自然基金面上项目 81470978

国家自然基金面上项目 81270834

详细信息

通讯作者:
孙启全, Email:sunqiquan@hotmail.com

中图分类号: R617
计量
- 文章访问数: 171
- HTML全文浏览量: 198
- PDF下载量: 19
- 被引次数: 0
出版历程
- 收稿日期: 2015-05-14
- 网络出版日期: 2021-01-19
- 刊出日期: 2015-07-15

摘要

摘要: 抗体介导的排斥反应(AMR)是移植肾排斥反应的一种重要类型, 也是导致移植肾丢失的首要原因。与T细胞介导的排斥反应相比, AMR临床症状重、救治困难、预后差, 越来越受到移植科医师的重视。本文就AMR的发病机制进行综述, 从抗体生成、免疫激活、移植肾功能障碍等方面简要介绍相关研究进展。
- 肾移植 /
- 抗体介导的排斥反应 /
- 供体特异性抗体 /
- C4d

HTML全文

参考文献(42)

[1]	Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure:the dominant role of antibody-mediated rejection and nonadherence[J]. Am J Transplant, 2012, 12(2):388-399. doi: 10.1111/j.1600-6143.2011.03840.x
[2]	Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation:new concepts in diagnosis and treatment[J]. Curr Opin Nephrol Hypertens, 2002, 11(6):609-618. doi: 10.1097/00041552-200211000-00007
[3]	Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure[J]. Am J Transplant, 2009, 9(11):2532-2541. doi: 10.1111/ajt.2009.9.issue-11
[4]	Süsal C, Döhler B, Opelz G. Presensitized kidney graft recipients with HLA class Ⅰ and Ⅱ antibodies are at increased risk for graft failure:a Collaborative Transplant Study report[J]. Hum Immunol, 2009, 70(8):569-573. doi: 10.1016/j.humimm.2009.04.013
[5]	Amico P, Hönger G, Mayr M, et al. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads[J]. Transplantation, 2009, 87(11):1681-1688. doi: 10.1097/TP.0b013e3181a5e034
[6]	Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation[J]. J Am Soc Nephrol, 2010, 21(8):1398-1406. doi: 10.1681/ASN.2009101065
[7]	Otten HG, Verhaar MC, Borst HP, et al. Pretransplant donor-specific HLA class-Ⅰ and -Ⅱ antibodies are associated with an increased risk for kidney graft failure[J]. Am J Transplant, 2012, 12(6):1618-1623. doi: 10.1111/ajt.2012.12.issue-6
[8]	Panigrahi A, Gupta N, Siddiqui JA, et al. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss[J]. Hum Immunol, 2007, 68(5):362-367. doi: 10.1016/j.humimm.2007.01.006
[9]	Lee PC, Ozawa M, Hung CJ, et al. Eighteen-year follow-up of a retrospective study of HLA antibody on kidney graft survival[J]. Transplant Proc, 2009, 41(1):121-123. doi: 10.1016/j.transproceed.2008.10.078
[10]	Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival[J]. Am J Transplant, 2007, 7(2):408-415. doi: 10.1111/ajt.2007.7.issue-2
[11]	Willicombe M, Roufosse C, Brookes P, et al. Antibody-mediated rejection after alemtuzumab induction:incidence, risk factors, and predictors of poor outcome[J]. Transplantation, 2011, 92(2):176-182. doi: 10.1097/TP.0b013e318222c9c6
[12]	Uchida K, Tominaga Y, Haba T, et al. ABO-incompatible renal transplantation:dissociation of ABO antibodies[J]. Transplant Proc, 1998, 30(5):2302-2303. doi: 10.1016/S0041-1345(98)00631-9
[13]	Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy[J]. Am J Transplant, 2004, 4(8):1315-1322. doi: 10.1111/ajt.2004.4.issue-8
[14]	Sun Q, Liu Z, Chen J, et al. Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection[J]. Clin J Am Soc Nephrol, 2008, 3(5):1479-1486. doi: 10.2215/CJN.04451007
[15]	Monaco AP, Morris PJ. Editorial commentary:increasing focus on antibodies[J]. Transplantation, 2014, 98(Suppl 3):S1-S2. https://www.researchgate.net/publication/264503204_Editorial_Commentary_Increasing_Focus_on_Antibodies
[16]	刘丹, 胡娟, 刘萍, 等.肾移植受者血清抗血管内皮细胞特异性抗体的提取和纯化[J].器官移植, 2015, 6(3):146-151. http://www.organtranspl.com/browse/detail/qkid/33/id/76.html Liu D, Hu J, Liu P, et al. Extraction and purification of serum specific endothelial cell antibody of renal transplant recipients[J]. Organ Transplant, 2015, 6(3):146-151. http://www.organtranspl.com/browse/detail/qkid/33/id/76.html
[17]	Jackson AM, Sigdel TK, Delville M, et al. Endothelial cell antibodies associated with novel targets and increased rejection[J]. J Am Soc Nephrol, 2015, 26(5):1161-1171. doi: 10.1681/ASN.2013121277
[18]	Baştürk B, Kantarolu B, Noyan ZA, et al. Association between panel reactive antibody and antiendothelial cell antibody positivity in kidney transplant patients[J]. Exp Clin Transplant, 2015, 13(Suppl 1):269-272. http://pubmed.cn/25894170
[19]	Sun Q, Cheng Z, Cheng D, et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection[J]. Kidney Int, 2011, 79(6):655-662. doi: 10.1038/ki.2010.437
[20]	Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation[J]. Transplantation, 2013, 95(1):19-47. doi: 10.1097/TP.0b013e31827a19cc
[21]	Zou Y, Heinemann FM, Grosse-Wilde H, et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry[J]. Hum Immunol, 2006, 67(3):230-237. doi: 10.1016/j.humimm.2006.02.017
[22]	Zou Y, Stastny P, Süsal C, et al. Antibodies against MICA antigens and kidney-transplant rejection[J]. N Engl J Med, 2007, 357(13):1293-1300. doi: 10.1056/NEJMoa067160
[23]	Ming Y, Hu J, Luo Q, et al. Acute antibody-mediated in presence of MICA-DSA and successful renal re-transplant with negative-MICA virtual crossmatch[J]. PLoS One, 2015, 10(5):e0127861. doi: 10.1371/journal.pone.0127861
[24]	Mehra NK, Siddiqui J, Baranwal A, et al. Clinical relevance of antibody development in renal transplantation[J]. Ann N Y Acad Sci, 2013, 1283:30-42. doi: 10.1111/nyas.12034
[25]	Dragun D. The role of angiotensin Ⅱ type 1 receptor-activating antibodies in renal allograft vascular rejection[J]. Pediatr Nephrol, 2007, 22(7):911-914. doi: 10.1007/s00467-007-0452-z
[26]	Yamaguchi Y. Reviews on mysterious vascular endothelial cells in renal allografts[J]. Clin Transplant, 2012, 26(Suppl 24):13-19. https://www.ncbi.nlm.nih.gov/pubmed/22747470
[27]	Wahrmann M, Exner M, Schillinger M, et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients[J]. Am J Transplant, 2006, 6(5 Pt 1):1033-1041. https://www.researchgate.net/publication/7169518_Pivotal_Role_of_Complement-Fixing_HLA_Alloantibodies_in_Presensitized_Kidney_Allograft_Recipients
[28]	Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria:an addition to the Banff 97 classification of renal allograft rejection[J]. Am J Transplant, 2003, 3(6):708-714. doi: 10.1034/j.1600-6143.2003.00072.x
[29]	Lee CY, Lotfi-Emran S, Erdinc M, et al. The involvement of FcR mechanisms in antibody-mediated rejection[J]. Transplantation, 2007, 84(10):1324-1334. doi: 10.1097/01.tp.0000287457.54761.53
[30]	Yamakuchi M, Kirkiles-Smith NC, Ferlito M, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis[J]. Proc Natl Acad Sci U S A, 2007, 104(4):1301-1306. doi: 10.1073/pnas.0602035104
[31]	Morrell CN, Murata K, Swaim AM, et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody[J]. Circ Res, 2008, 102(7):777-785. doi: 10.1161/CIRCRESAHA.107.170332
[32]	Haas M. Pathology of C4d-negative antibody-mediated rejection in renal allografts[J]. Curr Opin Organ Transplant, 2013, 18(3):319-326. doi: 10.1097/MOT.0b013e32835d4daf
[33]	Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report:inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions[J]. Am J Transplant, 2014, 14(2):272-283. doi: 10.1111/ajt.12590
[34]	Cosio FG, Gloor JM, Sethi S, et al. Transplant glomerulopathy[J]. Am J Transplant, 2008, 8(3):492-496. doi: 10.1111/ajt.2008.8.issue-3
[35]	Sun Q, Huang X, Jiang S, et al. Picking transplant glomerulopathy out of the CAN:evidence from a clinico-pathological evaluation[J]. BMC Nephrol, 2012, 13:128. doi: 10.1186/1471-2369-13-128
[36]	Sun Q, Cheng D, Zhang M, et al. Predominance of intraglomerular T-bet or GATA3 may determine mechanism of transplant rejection[J]. J Am Soc Nephrol, 2011, 22(2):246-252. doi: 10.1681/ASN.2010050471
[37]	Sun Q, Zhang M, Xie K, et al. Endothelial injury in transplant glomerulopathy is correlated with transcription factor T-bet expression[J]. Kidney Int, 2012, 82(3):321-329. doi: 10.1038/ki.2012.112
[38]	Li X, Sun Q, Zhang M, et al. The diagnostic value of transcription factors T-bet/GATA3 ratio in predicting antibody-mediated rejection[J]. Clin Dev Immunol, 2013:460316. https://www.hindawi.com/journals/jir/2013/460316/ref/
[39]	王军祥, 钟山, 王筱啸, 等.灵长类动物ABO血型不合肾移植后超急性排斥反应模型的建立[J].中华器官移植杂志, 2014, 35(7):421-425. http://d.wanfangdata.com.cn/Periodical/zhqgyz98201407010 Wang JX, Zhong S, Wang XX, et al. Establishment of a hyperacute rejection model in ABO-incompatible renal allotransplantation in non-human primates[J]. Chin J Orgn Transplant, 2014, 35(7):421-425. http://d.wanfangdata.com.cn/Periodical/zhqgyz98201407010
[40]	Terasaki PI. A personal perspective:100-year history of the humoral theory of transplantation[J].Transplantation, 2012, 93(8):751-756. doi: 10.1097/TP.0b013e3182483713
[41]	Sun Q, Yang Y. Late and chronic antibody-mediated rejection:main barrier to long term graft survival[J]. Clin Dev Immunol, 2013:859761. https://www.researchgate.net/publication/258503880_Late_and_Chronic_Antibody-Mediated_Rejection_Main_Barrier_to_Long_Term_Graft_Survival
[42]	Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure[J]. Am J Transplant, 2009, 9(11):2520-2531. doi: 10.1111/ajt.2009.9.issue-11